$ESLA
Estrella Immunopharma, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Emeryville, CA
ESLA chart
What traders are saying about $ESLA
Latest postsEstrella Immunopharma, Inc. news
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga ·
- Top 5 Further Gainers Among the Market Movers on November 10, 2026: AAON (NASDAQ:AAON) +27.03%, Estrella Immunopharma (NASDAQ:ESLA) +26.48%, Senseonics (NASDAQ:SENS) +26.12%, Cheche Group (NASDAQ:CCG) +23.30%, ATA Creativity
kalkine.ca ·
- Top 5 Healthcare and Biotech Gainers Among the Market Movers on November 10, 2026: PepGen (NASDAQ:PEPG) +159.83%, Autonomix Medical (NASDAQ:AMIX) +51.76%, Nano-X Imaging (NASDAQ:NNOX) +45.14%, Humacyte (NASDAQ:HUMA) +28.08
kalkine.ca ·
- Why Did Estrella Immunopharma (NASDAQ:ESLA) Rise 26.48% on the US Market Movers List on November 10, 2026?
kalkine.ca ·
- Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors
Yahoo Finance ·
- Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
Yahoo Finance ·
- Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Yahoo Finance ·
- ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial
Yahoo Finance ·
- Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Yahoo Finance ·
- Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Yahoo Finance ·
- Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Yahoo Finance ·
- Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
Yahoo Finance ·
Estrella Immunopharma, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$13.1M | -$7.3M | -$11.1M | -$996,104 |
| Diluted EPS | $-0.35 | $-0.27 | $-36.35 | – |
| Total assets (year end) | $3.2M | $3.1M | $9.4M | $9.7M |
| Cash and equivalents (year end) | $1.4M | $916,916 | $9.0M | $40,802 |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Estrella Immunopharma, Inc.
- Ticker
- ESLA (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Emeryville, CA
- Fiscal year end
- December 31
- SEC CIK
- 1844417
- Former names
- TradeUP Acquisition Corp.
Frequently asked questions
What exchange is Estrella Immunopharma, Inc. listed on?
Estrella Immunopharma, Inc. trades on the Nasdaq under the ticker symbol ESLA.
What industry is Estrella Immunopharma, Inc. in?
Estrella Immunopharma, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Estrella Immunopharma, Inc. headquartered?
Estrella Immunopharma, Inc.'s business address on file with the SEC is in Emeryville, CA.
When does Estrella Immunopharma, Inc.'s fiscal year end?
Estrella Immunopharma, Inc.'s fiscal year ends on December 31.